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Abstract This paper reviews advances in epilepsy in
recent years with an emphasis on therapeutics and under-
lying mechanisms, including status epilepticus, drug and
surgical treatments. Lessons from rarer epilepsies regard-
ing the relationship between epilepsy type, mechanisms
and choice of antiepileptic drugs (AED) are explored and
data regarding AED use in pregnancy are reviewed. Con-
cepts evolving towards a move from treating seizures to
treating epilepsy are discussed, both in terms of the
mechanisms of epileptogenesis, and in terms of epilepsy’s
broader comorbidity, especially depression.
Keywords Epilepsy  Classification  Status epilepticus 
Treatment  Pregnancy  Epileptogenesis
Definitions and classification
Definitions in epilepsy have always been problematic
[1–5]. The disorder is characterised by seizures but not all
seizures are due to epilepsy—febrile seizures or drug
induced seizures, for example. Earlier classifications
sought to reconcile these difficulties by describing different
electroclinical syndromes but new data from modern
imaging and genetics need to be incorporated.
Diagnosis is difficult because in practice, the diagnostic
electrical hallmark of epilepsy may be absent interictally,
especially in adults or if seizures are infrequent and
interictal epileptiform discharges may occasionally be
present in those without seizures. Moreover, in some
instances, an ‘‘epileptic EEG’’ may be associated with an
epileptic encephalopathy, in which overt seizures may be
few or none, such as Landau–Kleffner syndrome, and a
cognitive disorder dominates the presentation.
The International League Against Epilepsy recently
consulted in an attempt to synthesise a consensus view [6],
whose output will be published in 2017. The result promises
to be useful and pragmatic, recognizing that the syndromes
are multifaceted; any one case defined by an association of
clinical, electrophysiological, etiological and comorbid
factors. It also accepts that it is not always known if seizures
are part of focal or generalized epilepsy and that in some
cases, such as tuberous sclerosis, genetic and structural
causes overlap. Some terms will be dropped, for example,
childhood epilepsies where the seizures remit will be called
pharmacoresponsive rather than benign, recognizing that
children whose seizures remit may nevertheless have sig-
nificant persisting psychosocial comorbidities.
The ILAE has also pondered the question of whether a
single seizure may be considered to be epilepsy [7] and
concluded that it may if there is a greater than 60% chance
of another seizure; a risk conferred by the presence of EEG
spikes or a major structural aetiology. Epilepsy may be
considered to have gone away after ten years with no sei-
zures and with no treatment. This approach has pragmatic
utility, rather than mechanistic validity and is useful in
allowing driving regulatory authorities to treat those with
lower risk more leniently and may be helpful in deciding
when to treat medically after a single seizure [8].
Some frontal lobe epilepsies may be particularly diffi-
cult to diagnose, often with non-diagnostic ictal scalp
EEGs and some were initially considered to be a movement
disorder, e.g. ‘‘paroxysmal nocturnal dystonia’’ [9] in
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which its epileptic basis was shown later [9, 10]. The sit-
uation has become more complex with the discovery that
patients with frontal lobe epilepsy may also have epileptic
nocturnal wandering, with similarities to parasomnias and
also brief nocturnal movements which are not due to sei-
zure discharges but may be a release phenomenon of
interictal discharges [11]. They may suffer also from non-
epileptic parasomnias more frequently than the general
population. In the new classification, the phenomenon will
be renamed ‘‘Sleep-related hypermotor epilepsy (SHE)’’.
Status epilepticus and limbic encephalitis
The ILAE recently defined status epilepticus as: ‘‘a condition
resulting either from the failure of the mechanisms respon-
sible for seizure termination or from the initiation of mech-
anisms, which lead to abnormally, prolonged seizures (after
time point t1). It is a condition, which can have long-term
consequences (after time point t2), including neuronal death,
neuronal injury, and alteration of neuronal networks,
depending on the type and duration of seizures’’ [12].
Timepoint t1 is at 5 min after seizure onset, when it is rec-
ognized for generalized tonic–clonic status epilepticus that
evolution to status is increasingly likely and when treatment
should be initiated. T2 is at 30 min, after which there is
increasing risk of irreversible consequences. Status is divi-
ded along four axes; semiology, aetiology, EEG correlates
and age. These axes align with the prognosis of status, which
when adequately treated is determined by cause and the age
and gender of the patient. The electroclinical state is another
prognosticator; subtle status evolving from convulsive status
has a particularly poor prognosis [13, 14].
The impressive out-of-hospital randomized, double-
blind RAMPART study has shown that IM midazolam is at
least as effective as IV lorazepam in the early treatment of
status, in adults and children [15, 16], probably because IM
speed of administration of midazolam compensates for
speed of IV distribution of lorazepam. It has long been
known that the effect of benzodiazepines in status epilep-
ticus wears off very rapidly [17, 18] and it has subsequently
been demonstrated that GABAA receptor sensitivity is
reduced, sometimes long term [18]. Receptor trafficking
may be contributory [19, 20]. As well as a reduction in
inhibitory neurotransmitters, within 1 h of onset of status in
rats, there is an increase in surface NMDA receptors in
status, associated with increased excitation [21]. Cholin-
ergic mechanisms are also implicated, supported by the
observation that in pilocarpine induced status epilepticus;
the addition of scopolamine provides additional seizure
control, when combined with phenobarbital and benzodi-
azepines, raising the possibility of the use of drug combi-
nations in status [22].
Basic mechanisms are starting to align with clinical
evidence in the initial treatment of status with benzodi-
azepines, but thereafter the evidence is less clear. Initial
uncontrolled reports suggested a 70% success rate for the
treatment of status epilepticus with levetiracetam [23], but
a recent randomized controlled trial of out-of-hospital
clonazepam plus either levetiracetam or placebo was
abandoned because of a lack of benefit in the levetiracetam
arm [24]. This mirrors the finding that diazepam plus
phenytoin confers no additional benefit to lorazepam alone
at 12 h [14] and raises questions around the appropriate
timing of the addition of AED to benzodiazepines. It also
emphasizes the importance of properly controlled studies
in an area where few have been undertaken. Shorvon et al.
have undertaken meta-analyses of existing therapies
[25–27]. From generally poor quality studies of lacosa-
mide, levetiracetam, phenobarbital, phenytoin or valproate
in benzodiazepine resistant status, they found efficacy
ranging from 50% (phenytoin), to levetiracetam (68.5%),
phenobarbital (58–84%) and valproate 76%. Lacosamide
treatments were too few to give figures. The conclusion
remains that all these drugs may be useful but there is no
clear guidance on choice. The caution with which data
from uncontrolled studies must be interpreted is high-
lighted by a recent randomized study of valproate versus
phenobarbital which showed a 44% response to valproate
and an 81% response to phenobarbital. However, in chil-
dren, valproate may have fewer adverse effects and better
efficacy than phenobarbital [28, 29] and similar efficacy to
phenytoin [30]. But children may not be comparable to
adults with a greater proportion of generalized epilepsies,
more responsive to valproate. Future options include
derivatives of valproate such as valnactomide and butyl-
propylacetamide, which may be more potently antiepileptic
and less teratogenic in animal studies [31].
For status epilepticus which remains refractory to a
second line AED, a range of intravenous benzodiazepines
or anaesthetic agents may be considered and again Shorvon
et al. found that studies are of poor quality. They found that
35% of patients in these studies died and a further 13% had
severe neurological deficits and 13% mild neurological
deficits on recovery. Studies underway may help answer
some of these questions [32, 33]. Ketamine’s role in
blocking NMDA receptors [34] has led to it become
increasingly popular in the treatment of refractory status,
with some efficacy on the basis of uncontrolled retro-
spective series [35–37]. A randomized trial in children is
planned [38]. A recent trial of hypothermia showed no
benefit at 90 days [39].
It is increasingly recognized that some patients with
refractory status epilepticus, where the cause was previ-
ously unrecognized, may be suffering from an antibody
mediated encephalopathy, ‘‘limbic encephalitis’’.
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Antibodies implicated include LGI1 and NMDA, with
CASPR less associated with seizures [40, 41]. More
recently, GABAB and AMPA receptors have been impli-
cated in some cases [42]. A specific phenotype of very
brief, frequent and highly focal, faciobrachial dystonic
seizures is almost pathognomonic of LGI1 associated dis-
ease, often heralding a more severe encephalopathy [43]
and providing an opportunity to intervene at an earlier
stage. Limbic encephalitis exhibits characteristic changes
on MRI in the mesial temporal structures, especially the
amygdalae [44] and responds primarily to immunotherapy
and treatment of any associated tumour, rather than to AED
[41, 45]. Early suspicion of the diagnosis and treatment,
even before definitive serological confirmation, is recom-
mended. Many patients will recover with appropriate
treatment but may be left with ongoing epilepsy and hip-
pocampal sclerosis is a reported outcome [46]. The extent
to which epilepsy in patients, who have not suffered limbic
encephalitis, may be attributable to antibody-mediated
disease is an area of exploration which may open new
avenues of treatment for chronic epilepsy. Small cohorts
suggest increased rates of antibody positivity but their
significance is not yet clear [47, 48].
Pharmacological treatment of epilepsy
and underlying mechanisms/genetics
In 2000, Kwan and Brodie [49] found that 63% of unselected
patients in an epilepsy service were rendered seizure free
with medication. Since then despite numerous antiepileptic
drugs becoming available, they found that the chance of a
patient, who is diagnosed in 2017 becoming seizure free, has
changed little [50]. Some studies are more optimistic;
refractory epilepsy may have a greater chance of 12-month
remission with or without AED change [51–53] at around 5%
per year and although up to 40% may relapse [51], many of
these may have a second longer remission.
The broad sweep of AEDs, generally affecting ion
channels or neurotransmitters is unchanged, but there is
slowly increasing evidence for a differential effect in
specific syndromes.
Of established epilepsy drugs, ethosuximide, often for-
gotten by adult neurologists, has the most specific mechanism
in relation to its role in the absence epilepsy. It acts on T-type
calcium channels [54], implicated in the thalamocortical dis-
turbance believed for decades to underlie generalized
epilepsies [55]. Valproate and ethosuximide have clearly
demonstrated greater efficacy over lamotrigine in childhood
absence epilepsy [56]. A small, non-randomized study has
suggested that ethosuximide may be also associated with a
greater chance of long-term remission [57]. In a mouse model
of absence epilepsy, Bomben et al. [58] selectively ablated
P/Q channels in the neurons of layer VI that provide the
descending cortical projection to the thalamus. This produced
spike-wave activity with clinical absences suppressed by
ethosuximide. This very selective lesion supports the view
that a highly specific cortical abnormality is necessary and
sufficient to generate the thalamocortical oscillations of
absence epilepsy. Not all patients respond equally to medi-
cation. A clinical imaging and EEG study, comparing those
patients responsive to valproate to those who are resistant,
suggested different patterns of activation may underlie the
varying therapeutic responses [59].
Despite strong epidemiological evidence of a genetic
basis of IGE, relevant genes remain elusive, hampering
efforts to identify specific drug targets. A recent genome
wide association study suggested links to SCN1A, a known
cause of GEFS?, protocadherin PCDH7 and PCDH19,
both known to be associated with epilepsy and learning
disability [60]. An analysis of microdeletions in general-
ized epilepsy showed an increased burden (7.3%) com-
pared to controls (4%) and specific involvement of a range
of genes known to be important in epilepsy, psychiatry and
neurodevelopment [61].
The first major application of pharmacogenetics in epi-
lepsy, and probably still the most widely applicable, has
been the identification of patients from South East Asia
who are HLA-B*1502 positive, putting them at high risk
for Stevens–Johnson syndrome from carbamazepine and
the elimination of this life-threatening complication by pre-
treatment screening [62, 63]. Genetic understanding is
creeping into other areas of pharmacological therapeutics.
It has been realized for a number of years that sodium
channel blocking drugs may be deleterious for children
with Dravet syndrome [64, 65], although this may not be so
clear for adult patients [66]. It is now known that Dravet
syndrome is commonly due to a genetic truncations leading
to total loss of function or missense mutations causing
partial loss of function of the sodium channel, usually
SCN1A [67, 68], which is located on inhibitory interneu-
rons and causes hyperexcitability and seizures as a result of
loss of function. A previously empirical observation of
relative AED efficacy is now underpinned by a mechanistic
understanding, which can guide drug choice. Mutations of
the SCN8A gene are also associated with epilepsy, some-
times with a Dravet-like syndrome [69]. However, the
phenotype may depend on the pathophysiology of the
mutation, which may be a gain or a loss of function [70]. In
four children with epileptic encephalopathy onset in the
first months of life, Boerma described a response to
phenytoin [71]. One of these had been demonstrated to
have a gain of function mutation.
There are a number of other instances where rare
monogenic cases of epilepsy have been evaluated in detail
and treatment tailored to the identified pathophysiological
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mechanism, with varying success. Most consistently
effective is the use of ketogenic diet to switch cerebral
energy metabolism away from glucose in patients with
Glut-1 deficiency, which may be dramatically successful
[72, 73]. Retigabine (ezogabine) increases activity at
KCNQ2 channels [74] and has been used to treat the
neonatal epileptic encephalopathy associated with reduced
function mutations of the KCNQ2 channel with some
success [75]. Unfortunately, this drug is to be withdrawn
from use in 2017 because of the pigmentary changes it may
induce in skin, mucosae and eyes [76]. GRIND2 mutations
resulting in gain of activity of the NMDA receptor may
cause balloon swelling and cell death. Children with a
severe encephalopathy due to this mutation may possibly
benefit from treatment with memantine, more generally
used in Alzheimer’s disease which inhibits this channel
[77]. KCNT1 encodes a sodium-activated potassium
channel and has been implicated in the migrating partial
epilepsy of childhood and in autosomal dominant frontal
lobe epilepsy, both causing a gain of function [78]. Two
children with this mutation and a severe epilepsy pheno-
type were helped by the administration of quinidine [79].
These cases illustrate the importance of not only an elec-
troclinical and genetic diagnosis of these epilepsies but also
delineation of the specific pathophysiology of the mutation
to enable drug choice, which may include opportunities
beyond those conventionally used in the antiepileptic
armamentarium.
Epileptogenesis and inflammation
Another focus is the mechanisms of epileptogenesis; the
process from initiation of pathological changes to the
development of epilepsy and possibly the maintenance of
epilepsy. There are changes, which involve altered gene
expression, inflammation, protein production and changes
in connectivity, which may all be the target for drugs to
suppress epileptogenesis. One of the most studied path-
ways links to the rapamycin (mTOR) pathway (Fig. 1).
Upregulation of mTOR, a serine/threonine protein kinase,
occurs as a result of the TSC1 and TSC2 mutations of
tuberous sclerosis (TS) complex. Other mutations in the
pathway may be associated with overgrowth in megalen-
cephaly [80]. mTOR has a role in protein synthesis and
inhibition of mTOR, cell growth and replication by ever-
olimus, a rapamycin analogue, has been shown to reduce
overgrowth of malignantly transformed tubers [81]. Ani-
mal models have shown an antiepileptic effect of mTOR
inhibition [82] but this has been more difficult to demon-
strate in humans. However, a recent double-blind study of
366 patients showed a dose-related seizure reduction of up
to 40% with everolimus, in patients with TS [83].
However, mTOR inhibitors may also have a direct effect
on Kv1.1 ion channels, independent of epileptogenesis
[84], blurring their possible mechanism in seizure
suppression.
Whilst immunological mechanisms are clearly impli-
cated in the aetiology of certain epilepsies such as limbic
encephalitis [85] or Rasmussen encephalitis [86], increas-
ing attention has been given to them in commoner forms of
epilepsy. There is broad evidence for their significance,
especially from animal studies and involving cytokines,
changes in the blood brain barrier and pathological alter-
ations associated with altered excitability [87–94]. Patho-
logical examination of resected human specimens of focal
cortical dysplasia [95] has also shown substantial increases
in mRNA expression of Toll-like receptors 2 and 4 and
associated with high-mobility group box protein 1,
restricted to astrocytes and microglia in pathological tissue.
These interact through interleukin IL1-b. Microglia acti-
vation appears increased more in focal cortical dysplasia
(FCD) type II than in FCD I, associated with the migration
of activated lymphocytes and activation of the mTOR
pathway, linking inflammation to epileptogenesis [96]. A
recent systematic review and meta-analysis [97] has
described increased CNS levels of interleukins of the IL1
family as well as of chemocytokines CCL 3-5, which are
involved in monocyte and lymphocyte migration. IL6
appears to be elevated in serum but not in CNS. A recent
study of patients with moderate to severe cerebral trauma
found a relationship between cerebrospinal fluid IL1-b
levels and an allelic variant of the IL1-b gene to the risk of
developing epilepsy [98]. This provides the first evidence
of a biomarker that might be used to predict epilepsy after
an epileptogenic insult and possibly a means of pharma-
cological intervention. These may need to be complex; a
recent study suggested a single intervention was inadequate
and a cocktail of anti-inflammatory drugs was required to
prevent epileptogenesis [99]. A small case series of
intractable childhood onset epilepsy has already been
treated successfully with human recombinant IL-1 receptor
antagonist (Anakinra\) [100] and it is hopeful that, as there
are already many drugs affecting the immune system and
some affecting the blood brain barrier, that this will prove a
fertile area for development.
Recently, mutations of the DEPDC5 (DEP domain
containing 5, involved in g-protein signalling) gene have
been demonstrated in patients with cortical dysplasia and in
up to 12% of small families of patients with familial focal
epilepsy phenotypes, including ADNFLE without demon-
strable lesions [101–103]. This gene is involved in the
same GATOR pathway as mTOR. Although the GATOR
(gap activity towards RAG’s) pathway is generally asso-
ciated with protein synthesis, it appears to reduce the levels
of Kv1.1 potassium channels in hippocampal pyramidal
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neurons increasing seizure expression, which can be
reversed by inhibitors [104]. These findings link lesional
and non-lesional ion channel related epilepsies to the same
pathway, providing a potential opportunity for the wider
use of inhibitors in treatment.
Although the scope is expanding, the relationship of
these mechanisms to the majority of epilepsies, those
triggered by a neurological insult (focal epilepsies) or a
complex genetic trait (generalized epilepsies) remains to be
established. It has long been recognized that epilepsy due
to trauma is more likely in those with a family history of
epilepsy [105] providing a potential to link to genetic
mechanisms. But the development of epilepsy may take
20 years [105, 106]. The key will be to identify those
patients at high risk and to find a low risk preventative
treatment akin to aspirin in stroke and very large, long-term
follow up studies, will be needed to establish efficacy.
Biomarkers such as IL1-b for evolving epileptogenesis are
needed to identify high risk patients and to act as drug
targets.
Antiepileptic drug trials
Despite being a common disorder, the number of high
quality trials of antiepileptic drugs is small. Trials of new
AED are normally in the form of an add-on therapy in
refractory partial epilepsy, usually with the end point of a
50% reduction of seizures. This may be realistic in showing
a biological effect but does not confer the psychosocial
benefits of seizure freedom, and therefore drugs enter the
market with the knowledge that they will not dramatically
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alter the burden of refractory epilepsy. The Federal Drug
Administration in the US requires monotherapy trials
against placebo and the European Medicines Agency
requires head-to-head trial of active agents. Consequently,
results cannot cross the Atlantic, delaying introduction and
increasing cost for manufacturers. Both types of trials have
their merits. The result is a non-systematic hotchpotch of
evidence in relation to monotherapy in epilepsy. Whilst the
pragmatic study SANAD has guided many UK clinicians to
lamotrigine as first line in monotherapy for focal epilepsy
[107], carbamazepine remains a drug of choice in many
countries and studies [108]. A recent study has shown that
zonisamide is non-inferior to carbamazepine in new onset
focal epilepsy in adults [109]. A large study of 1688 new
onset patients compared time to withdrawal of levetirac-
etam in two arms to first choice carbamazepine or valproate
in monotherapy in adults [110]. Overall, the drugs per-
formed similarly but in a post hoc analysis, levetiracetam
withdrawal rate was lower in those over 60, especially in
comparison to carbamazepine, with fewer adverse effects
rather than greater efficacy [111].
The repertoire of AED considered effective in IGE has
traditionally been more restricted that for focal epilepsy.
Case reports have supported the use of lacosamide
[112, 113] and it is the subject of ongoing larger scale
studies. Perampanel has been found to be effective as an
add-on for refractory generalized epilepsy with tonic–clo-
nic seizures [114].
Cannabis contains approximately 80 different active
cannabinoids and was used in the nineteenth century as an
AED [115]. It has been known for many years to be an
antagonist at NMDA receptors with antiepileptic activity
[116]. D9 tetrahydrocannabinol is the main psychoactive
component of cannabis, acting on THC1 and THC2
receptors but other components, especially cannabidiol
(CBD) do not act on these receptors, are not psychoactive.
They may have medicinal properties through a range of
other actions [117]. Clinical studies in the 1970s and 80s
reviewed in [117] pointed to antiepileptic effects and recent
anecdotal evidence and an open labelled trial have shown
benefit in epileptic encephalopathies such as Dravet syn-
drome [118, 119], which have had a profound social effect
in the United States, with parents moving their families to
states where cannabis is legal [120]. Although their
mechanisms point to a potential role for cannabinoids of
relevance to epilepsy [121], there are as yet, no good
studies to support their widespread use. The adverse effects
of natural cannabis are widely known [122] and a particular
problem for adolescents. Cannabinoids should be avoided
by those with epilepsy, especially the young, who are
already at risk of psychiatric problems, until good quality
trials support their use.
Epilepsy and comorbid depression
Data extracted from a US population survey of 340,000
households and those with epilepsy were compared to those
without [123]. Two percent had suffered with epilepsy and
reported increases in a range of disorders (Table 1). A
figure of approximately one third affected by depression is
consistent with numerous previous studies. The relation-
ship to epilepsy is complex. In studies of IGE, the epilepsy
and its impact may be important [124] but there is often
dissociation between a good seizure outcome and a poor
psychosocial outcome [125]. A key factor predicting out-
come relates to family environment support [126] but a
biological association is supported by the observation that
children and adults have an increased risk of psychiatric
disturbance, even before the onset of their epilepsy
[127, 128], and by a broad range of experimental studies
[129]. Interactions between epilepsy and depression may
include shared abnormalities in a number of neurotrans-
mitters including 5HT1A mechanisms [130, 131] and via
glutamate, where low-dose ketamine, an antiepileptic
NMDA antagonist, may have an impact on depression
[132]. These studies illustrate a bidirectional relationship of
epilepsy and depression, involving both biological and
psychosocial factors.
A common concern is that antidepressants may increase
seizures. The risk of de novo seizures from the use
antidepressants is 0.1% for newer drugs and 0.3% from
older drugs, e.g. tricyclics [133]. Exceptions may be
maprotiline, bupropion or clomipramine with a higher risk
[134] but overall, those in the treatment arm of antide-
pressant trials had fewer seizures than those in the placebo
arms [134]. In smaller studies of those with epilepsy at
therapeutic doses of antidepressants, many will experience
Table 1 Comorbidities in a nationwide US survey [123]
No epilepsy (%) Epilepsy (%)
Anxiety 13.9 22.4
Depression 25.6 32.5
Bipolar disorder 6.7 14.1
ADHD 5.5 13.2
Sleep disorder/apnea 13.6 19.6
Movement disorder/tremor 4.6 9.3
Migraine 20.6 27.9
Chronic pain 17.7 25.4
Fibromyalgia 7.5 15.4
Neuropathic pain 5.6 8.7
Asthma 16.6 20.7
Diabetes 15.2 15.2
Hypertension 36.7 36.2
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an improvement in their epilepsy [135]. A recent review
has brought together the newer mechanistic evidence,
showing that 5HT1A may mediate a number of actions,
which have antiepileptic effects, including increasing
GABA activity and reducing inflammatory cytokines and
those patients with epilepsy may have reduced PET ligand
binding at 5 HT1A sites [136]. In a mouse model of sudden
unexplained death in epilepsy, drugs acting on 5-HT3
receptors (fluoxetine, blocked by ondansetron) reduced
respiratory arrest in seizures, without affecting the seizures
themselves [137], a further possible mode of benefit of
antidepressants in epilepsy. Where possible, it may be
appropriate to avoid those antidepressants with pharma-
cokinetic interactions with AED, such as fluvoxamine,
paroxetine and fluoxetine. Hopefully, neurologists can now
encourage the use of antidepressants, especially as psy-
chiatric comorbidity is a greater determinant of quality of
life than seizure frequency in those with refractory epilepsy
[138].
Antiepileptic drugs and pregnancy
In recent years, information regarding major congenital
malformation (MCM) rates has been consolidated in epi-
lepsy and pregnancy registries. AED are divided into those
with reasonably quantified risk and those with insufficient
data. This becomes self-reinforcing with increased reluc-
tance to prescribe drugs of uncertain risk to those who may
conceive. The most recent data from the UK epilepsy and
pregnancy register, shows a very clear dose-related effect
with valproate risk 5% with\600 mg daily increasing to
11% at over 1000 mg. Carbamazepine at 2% risk when
given at \500 mg daily, 3% at 500–1000 mg and 5% at
[1000 mg. Lamotrigine had a less steep curve with 2% at
\200 mg, increasing to 3.5% over 400 mg daily [139].
These data are similar to those published from European
and US registries [140]. Oxcarbazepine, not widely used in
the UK, appears to have similar low risk to lamotrigine at
2.2% [141]. The risk for levetiracetam appears similarly
low at 0.7% in monotherapy, increasing in polytherapy
[142]. Added to the risk of MCM are concerns over more
subtle neurodevelopmental disturbances, including lower
IQ, autism and ADHD, which may conceivably arise from
exposure to valproate at any stage of pregnancy [143–146].
Although not widely used in pregnant women, topiramate
and zonisamide may be associated with significantly lower
birthweight [147]. Recent data have also shown the
importance of considering genetic factors in teratogenicity.
A family history of abnormalities increases the risk. The
risk to a second child, where a first was affected by an AED
may be as high as 17–36% [148, 149]. Clinicians must also
consider the risk to the mother of epilepsy in pregnancy
and data suggest a tenfold increase in mortality compared
to non-epilepsy controls, largely due to SUDEP [150].
Epilepsy surgery
Given the low chance of response to medical therapy after
the failure of two AED [49], this is the widely accepted
yardstick for defining refractoriness and the appropriate-
ness for consideration of resective epilepsy surgery. The
proportion of patients for whom surgery may be successful
is not clear, but is estimated as a maximum of around 2%
of the total cohort. With an incidence of 0.5%, in the USA
and a prevalence of 750,000, this translates to up to 3500
incident cases and 15,000 prevalent cases, in which surgery
might be considered. The rate of epilepsy surgery has
remained static at around 1500 cases per year [151, 152]
for over 20 years. The pattern of cases operated may be
changing with a reduction in mesial temporal sclerosis
[153], perhaps due to improved outcomes of childhood
febrile seizures. At the same time, the outcomes of
extratemporal epilepsies are improving with new diagnos-
tic techniques. The mortality of surgery is around 0.1–0.5%
[151], similar to the annual rate of SUDEP in refractory
epilepsy [154], i.e. the mortality of ongoing refractory
epilepsy exceeds the post-operative risk after one year.
Complication rates have reduced [155] and are around 3%
for major and 7% for minor complications; one of the
commonest complications is a visual field defect after
temporal lobectomy [151, 156]. The treatment is cost-ef-
fective in the long term, with sustained remission and close
to half of adult patients and 86% of children may be able to
stop their AEDs. Two recent studies have found risk factors
for seizure recurrence after post-operative drug withdrawal
included pre-operative seizure frequency and post-opera-
tive EEG abnormalities [157, 158]. They also found about
one third of those relapsing will not come back under
control with re-introduction of medication, especially those
with early recurrence, perhaps reflecting a less complete
surgical remission.
Health-related quality of life often returns to normal in
those who become seizure free [159]. Negative prognostic
factors include high seizure frequency and long duration at
baseline [160, 161]. Those with lesions such as cavernomas
or benign tumours may achieve 77% seizure freedom at
two years, even if surgery is undertaken after a long seizure
history [162].
Advances in epilepsy surgery include alternative meth-
ods to resective surgery; improvements in techniques of
case selection for surgery and neurostimulation techniques.
Radiosurgery for arteriovenous malformations may give
excellent outcomes for associated epilepsy and positive
prognostic factors have been reported to be presentation
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with haemorrhage rather than epilepsy and the absence of
post-treatment haemorrhage [163–165]. A recent meta-
analysis of stereotactic radiosurgery for mesial temporal
sclerosis [166] showed that the total number of patients
reported remains low (\200) but that half became seizure
free at a median of 14 months after treatment with a
complication rate of around 8% (excluding headache which
was more common) and rates of visual field defects similar
to open surgery. MRI-guided laser thermocoagulation has
been undertaken in a few patient with initially promising
results. Procedural morbidity is low and patients may be
admitted for just one day. It has been suggested as appro-
priate particularly for older patients. [167–170]. The elec-
trodes inserted for stereotactic EEG recording may also be
used to deliver a thermocoagulation induced lesion to the
surrounding brain, with a diameter of 4.5–7 mm. This has
been undertaken in patients with hypothalamic hamartoma,
for whom surgery is difficult and with a high success in
remission of the gelastic seizures associated with these
lesions [171]. Early indications are that this may be an
approach which can be undertaken in cases of focal cortical
dysplasia.
The identification of patients who will benefit from
epilepsy surgery relies on the demonstration of a single
brain region responsible for the epilepsy, which can be
safely resectable. Identification of a responsible lesion has
been demonstrated in numerous studies to predict a better
outcome [172]. Even in those where imaging is normal,
resection on the basis of an intracranial EEG abnormality is
more likely to result in seizure freedom if the resected
tissue is pathologically abnormal [173]. Increasing pre-
operative identification of pathology through improved
MRI, through higher field strengths up to 7 T in vivo and
enhancing 3 T with automated measures of hippocampal
volumes potentially gives a greater chance of identifying
candidates who may benefit from surgery [174–176]. In
those whom structural imaging remains negative, then
FDG-PET can aid in the decision making, either in favour
of surgery, e.g. in those thought to have non-dominant TLE
or against surgery in more complex cases [177, 178].
Magnetoencephalography is not widely used [179], but a
recent study demonstrated that if all MEG abnormal areas
were resected, prognosis was improved and MEG can be
used to target SEEG more successfully [180]. Tight clus-
tering of MEG abnormalities predicted a better outcome
than more dispersed abnormalities. High density EEG
source imaging using increased electrode number may also
be valuable in predicting the outcome of surgery [181].
Intravascular stent EEG, shown to be safe in sheep may be
a non-invasive method of intracranial EEG recording in the
future [182].
Where resective surgery is not possible, palliative
stimulation techniques may be considered. The most
established and widely used is vagus nerve stimulation
which is safe, with a low risk of complications, such as
infection, haematoma and vocal cord palsy [183]. An
analysis from the VNS registry combined with pooled
study data totaling 8423 patients [184] found that respon-
der rate, defined by a 50% seizure reduction, was 47% at
0–14 months and 63% at 24–48 months with seizure free
rates rising from 5–10% over the same period. Quality of
life measures also improved with VNS [185], which may
relate to seizure reduction, reduced AED load in associa-
tion with successful antiepileptic treatment or putative
effects of VNS on mood [186]. Responsive stimulation
involves a closed circuit of intracranial electrodes with
electrical stimuli delivered to the brain according to a
seizure detection paradigm. The circuit is often installed
following electrode placement in an unsuccessful attempt
to identify a surgical target. In 191 patients there was a
37.9% responder rate compared to 17.3% in the sham
group. [187]. Electrodes placed in the thalamus have been
associated with a 69% median reduction in seizure fre-
quency and a 35% rate of serious adverse events, including
infection in 10% and lead misplacement in 8% [188]. Other
targets under investigation include the nucleus accumbens
[189] and the cerebellum [190]. Optogenetic methods
[191], successful in animals, have not yet been applied in
humans.
Summary
A new classification of epilepsies will support the inte-
gration of novel aetiological and genetic factors with the
existing electroclinical classification and help identify
when a single seizure might be considered epilepsy on the
basis of an abnormal EEG or imaging. Midazolam IM has
emerged as the benzodiazepine of choice in out-of-hospital
treatment of status epilepticus and a valid alternative in
hospital, but good clinical studies are lacking beyond this
early stage. Limbic encephalitis is increasingly diagnosed
and primary treatment is immunotherapy rather than AED.
The significance of antibodies more generally in epilepsy
remains unclear. Most epilepsy treatment remains without
a clear evidence base but ethosuximide and valproate have
been demonstrated to be the most efficacious AED in
absence epilepsy. Perampanel and lacosamide are new
drugs which are emerging as treatments for tonic–clonic
seizures in generalized epilepsy. A small number of
specific genetic epilepsies have allowed personalized
treatment in specific cases but this has not yet had broader
application. Epileptogenesis is a fertile area of research and
everolimus, an inhibitor of the mTor pathway, has
demonstrated efficacy in epilepsy associated with TS,
showing the clinical potential of this avenue of research for
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the first time. Epilepsy and pregnancy registers are con-
solidating data pointing to the use of lamotrigine, leve-
tiracetam, carbamazepine and/or oxcarbazepine as those
AED with the lowest risk of major congenital malforma-
tions. New evidence has associated topiramate and zon-
isamide with low birth weight. Clinicians can treat
comorbid depression with most modern antidepressants,
reassured that there is little evidence of an adverse effect
on their patient’s epilepsy. Surgical treatment of epilepsy
remains under-utilised and the selection of patients for
surgical treatment of epilepsy is becoming more refined
with the use of functional imaging to support structural
imaging. Alternative ablative treatments are being explored
but are not yet widespread. Stimulation techniques other
than VNS are areas of research, which remain to find their
place.
Overall, recent epilepsy research has started to change
our thinking and approach to patients, as we slowly move
towards a more rational basis by which to treat this com-
mon condition.
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